Challenges in the diagnosis and management of acromegaly : a focus on comorbidities
Ver / Descargar
Fecha
2016-06-08Autor(es)
Abreu, AlinPinzón Tovar, Alejandro
Castellanos, Rafael
Valenzuela, Alex
Gomez Giraldo, Claudia Milena
Castellanos Pinedo, Alejandro
Pantoja Guerrero, Doly
Builes Barrera, Carlos Alfonso
Franco, Humberto Ignacio
Ribeiro-Oliveira Jr, Antônio
Vilar, Lucio
Jallad, Raquel S
Gaia Duarte, Felipe
Gadelha, Monica
Boguszewski, Cesar Luiz
Abucham, Julio
Naves, Luciana A
Musolino, Nina Rosa C
Justamante De Faria, Maria Estela
Rossato, Ciliana
Bronstein, Marcello D
Autor(es) Corporativo(s)
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Endocrinología
Tipo
Artículo de revista
ISSN
1386-341X / 1573-7403 (Electrónico)
COAR
Artículo de revistaCompartir este registro
Citación
Documentos PDF
Abstract
Introduction: Acromegaly is a rare, insidious disease resulting from the overproduction of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), and is associated with a range of comorbidities. The extent of associated complications and mortality risk is related to length of exposure to the excess GH and IGF-1, thus early diagnosis and treatment is imperative. Unfortunately, acromegaly is often diagnosed late, when patients already have a wide range of comorbidities. The presence of comorbid conditions contributes significantly to patient morbidity/mortality and impaired quality of life.
Methods: We conducted a retrospective literature review for information relating to the diagnosis of acromegaly, and its associated comorbidities using PubMed. The main aim of this review is to highlight the issues of comorbidities in acromegaly, and to reinforce the importance of early diagnosis and treatment.
Findings and conclusions: Successful management of acromegaly goes beyond treating the disease itself, since many patients are diagnosed late in disease evolution, they present with a range of comorbid conditions, such as cardiovascular disease, diabetes, hypertension, and sleep apnea. It is important that patients are screened carefully at diagnosis (and thereafter), for common associated complications, and that biochemical control does not become the only treatment goal. Mortality and morbidities in acromegaly can be reduced successfully if patients are treated using a multimodal approach with comprehensive comorbidity management.
Enlace al recurso
https://pubmed.ncbi.nlm.nih.gov/27279011/#affiliation-1Fuente
Pituitary; Volumen 19 Número 4 , Páginas 448 - 457 (2016)
Estadísticas Google Analytics
Colecciones
- Artículos [56]